Clinical Trial Update: Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating RBS2418 in combination with tremelimumab and durvalumab in participants with advanced unresectable hepatocellular carcinoma; r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Durvalumab (durvalumab)
• RBS2418
• Tremelimumab (tremelimumab)

Snippet

Sponsor: Riboscience, LLC. | Conditions: Advanced Unresectable Hepatocellular Carcinoma | Phase 2 | Status: RECRUITING